• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»hematology therapeutics

Can NovelMed Therapeutics challenge established PNH drugs with its Bb-targeting antibody Ruxoprubart?

By Soujanya Ravi on March 9, 2026   Pharma & Biotech  

Can NovelMed Therapeutics challenge established PNH drugs with its Bb-targeting antibody Ruxoprubart?

NovelMed Therapeutics advances Ruxoprubart for paroxysmal nocturnal hemoglobinuria with Phase II data and a new subcutaneous trial. Discover what comes next.

Can Hemab Therapeutics’ sutacimig finally deliver the first preventive therapy for Glanzmann thrombasthenia after FDA breakthrough designation?

By Pallavi Madhiraju on March 6, 2026   Pharma & Biotech  

Can Hemab Therapeutics’ sutacimig finally deliver the first preventive therapy for Glanzmann thrombasthenia after FDA breakthrough designation?

FDA grants Breakthrough Therapy Designation to Hemab Therapeutics’ sutacimig for Glanzmann thrombasthenia. Discover what this means for bleeding disorder treatment.

Recent Posts

  • Can Ono and Deciphera turn ONO-4578 into a global Phase 3 oncology contender?
  • Ranok Therapeutics pushes RNK08954 forward as KRAS G12D drug development heats up
  • Can Servier’s $2.65bn Edgewise deal reshape the muscular dystrophy drug race?
  • Can Convergent Therapeutics define the next prostate cancer standard after Lu-PSMA therapy?
  • Why T-CURX’s Pantherna acquisition could matter for the future of cell therapy manufacturing
  • Is Amgen’s bispecific lung cancer drug becoming a global standard after chemotherapy failure?
  • Fulgent Genetics’ oncology pivot gets sharper as FID-007 shows Phase 2 activity at ASCO 2026
  • Minghui and Qilu push MHB088C forward as prostate cancer ADC race tightens
  • Why Aphranel’s EU MDR approval could sharpen competition in CaHA dermal fillers
  • Oricell’s ASCO 2026 liver cancer data put GPC3 CAR-T back in the spotlight
  • Can Lilly turn Hanmi’s sonefpeglutide into the next long-acting GLP-2 rare disease bet?
  • Can enicepatide and petrelintide help Genentech build a differentiated obesity franchise?
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes